Atopic dermatitis (AD), also known as atopic eczema, is a long-term type of inflammation of the skin (
dermatitis).[2] It results in
itchy, red, swollen, and cracked skin.[2] Clear fluid may come from the affected areas, which can thicken over time.[2] AD may also simply be called
eczema, a term that generally refers to a larger group of skin conditions.[2][5]
Atopic dermatitis affects about 20% of people at some point in their lives.[2][4] It is more common in younger children.[3] Females are slightly more affected than males.[6] Many people outgrow the condition.[3]
While the condition may occur at any age, it typically starts in childhood, with changing severity over the years.[2][3] In children under one year of age, the face and limbs and much of the body may be affected.[3] As children get older, the areas on the insides of the knees and folds of the elbows and around the neck are most commonly affected.[3] In adults, the hands and feet are commonly affected.[3] Scratching the affected areas worsens the eczema and increases the risk of
skin infections.[2] Many people with atopic dermatitis develop
hay fever or
asthma.[2]
The cause is unknown but believed to involve
genetics,
immune system dysfunction, environmental exposures, and difficulties with the
permeability of the skin.[2][3] If one
identical twin is affected, the other has an 85% chance of having the condition.[7] Those who live in cities and dry climates are more commonly affected.[2] Exposure to certain chemicals or frequent hand washing makes symptoms worse.[2] While emotional stress may make the symptoms worse, it is not a cause.[2] The disorder is not
contagious.[2] A diagnosis is typically based on the signs, symptoms and
family history.[3]
Treatment involves avoiding things that make the condition worse, enhancing the skin barrier through skin care and treating the underlying skin inflammation.
Moisturising creams are used to make the skin less dry and prevent AD flare-ups. Anti-inflammatory
corticosteroid creams are used to control flares-ups.[3] Creams based on
calcineurin inhibitors (tacrolimus or pimecrolimus) may also be used to control flares if other measures are not effective.[2][8] Certain
antihistamine pills might help with itchiness.[3] Things that commonly make it worse include
house dust mite,
stress and seasonal factors.[9]Phototherapy may be useful in some people.[2] Antibiotics (either by mouth or topically) are usually not helpful unless there is secondary bacterial infection or the person is unwell.[10]Dietary exclusion does not benefit most people and it is only needed if food allergies are suspected.[11] More severe AD cases may need systemic medicines such as
cyclosporin,
methotrexate,
dupilumab or
baricitinib.
Other names of the condition include "infantile eczema", "flexural eczema", "prurigo Besnier", "allergic eczema", and "neurodermatitis".[1]
Signs and symptoms
Symptoms refer to the sensations that people with AD feel, whereas signs refers to a description of the visible changes that result from AD.
The main symptom of AD is
itching which can be intense. Some people experience burning or soreness or
pain.[2]
People with AD often have a generally dry skin that can look greyish in people with darker skin tones of colour. Areas of AD are not well defined, and they are typically inflamed (red in a light coloured skin or purple or dark brown in people with dark skin of colour).[12] Surface changes include:
thickening of the skin (lichenification) where the AD has been present for a long time.[2]
Eczema often starts on the cheeks and outer limbs and body in infants and frequently settles in the folds of the skin such as behind the knees, folds of the elbows, around the neck, wrists and under the buttock folds as the child grows.[13] Any part of the body can be affected by AD.[14]
AD commonly affects the eyelids, where an extra prominent crease can form under the eyelid due to skin swelling known as
Dennie-Morgan infraorbital folds.[15] Cracks can form under the ears which can be painful (infra-auricular fissure).[16][15]
The inflammation from AD often leaves "footprints" known as
postinflammatory pigmentation that can be lighter than the normal skin or darker. These marks are not scars and eventually go back to normal over a period of months providing the underlying AD is treated effectively.[17]
People with AD often have dry and scaly skin that spans the entire body, except perhaps the diaper area, and intensely itchy red, splotchy, raised
lesions to form in the bends of the arms or legs, face, and neck.[18][19][20][21][22]
Causes
The cause of AD is not known, although some evidence indicates environmental, immunologic, and potential genetic factors.[23]
Pollution
Since 1970, the rates of atopic dermatitis in the US and UK have increased 3-6 fold.[24] Even today, people who migrate from developing nations before the age of 4 years to industrialized nations experience a dramatic rise in the risk of atopic dermatitis and have an additional risk when living in urbanized areas of the industrial nation.[25] Recent work has shed light on these and other data strongly suggesting that early life industrial exposures may cause atopic dermatitis.[24][26] Chemicals such as
(di)isocyanates and
xylene prevent the skin bacteria from producing
ceramide-
sphingolipid family lipids.[24][26] Early life deficiency in these lipids predictive which children will go on to develop atopic dermatitis.[27][28][29][30] These chemicals also directly activate an itch receptor in the skin known as
TRPA1.[31] The industrial manufacturing and use of both xylene and diisocyanates greatly increased starting in 1970, which greatly expanded the average exposure to these substances. For example, these chemicals are components of several exposures known to increase the risk of atopic dermatitis or worsen symptoms including: wildfires, automobile exhaust, wallpaper adhesives, paints, non-latex foam furniture, cigarette smoke, and are elements of fabrics like
polyester,
nylon, and
spandex.[25][24][26]
Climate
Low
humidity, and low
temperature increase the prevalence and risk of flares in patients with atopic dermatitis.[32]
Genetics
Many people with AD have a family history or a personal history of
atopy. Atopy is a term used to describe individuals who produce substantial amounts of
IgE. Such individuals have an increased tendency to develop
asthma,
hay fever,
eczema,
urticaria and allergic rhinitis.[18][19] Up to 80% of people with atopic dermatitis have elevated total or allergen-specific IgE levels.[33]
About 30% of people with atopic dermatitis have mutations in the gene for the production of
filaggrin (FLG), which increase the risk for early onset of atopic dermatitis and developing asthma.[34][35] However, expression of filaggrin protein or breakdown products offer no predictive utility in atopic dermatitis risk.[28]
Hygiene hypothesis
According to the
hygiene hypothesis, early childhood exposure to certain microorganisms (such as
gut flora and
helminth parasites) protects against
allergic diseases by contributing to the development of the
immune system.[36] This exposure is limited in a modern "sanitary" environment, and the incorrectly developed immune system is prone to develop allergies to harmless substances.
Some support exists for this hypothesis with respect to AD.[37] Those exposed to dogs while growing up have a lower risk of atopic dermatitis.[38] Also, epidemiological studies support a protective role for helminths against AD.[39] Likewise, children with poor hygiene are at a lower risk for developing AD, as are children who drink unpasteurized milk.[39]
Allergens
In a small percentage of cases, atopic dermatitis is caused by sensitization to foods[40] such as milk, but there is growing consensus that
food allergy most likely arises as a result of skin barrier dysfunction resulting from AD, rather than food allergy causing the skin problems.[41] Atopic dermatitis sometimes appears associated with
coeliac disease and non-coeliac gluten sensitivity. Because a
gluten-free diet (GFD) improves symptoms in these cases,
gluten seems to be the cause of AD in these cases.[42][43] A diet high in fruits seems to have a protective effect against AD, whereas the opposite seems true for heavily processed foods.[39]
Exposure to
allergens, either from food or the environment, can exacerbate existing atopic dermatitis.[44] Exposure to dust mites, for example, is believed to contribute to the risk of developing AD.[45]
Role of Staphylococcus aureus
Colonization of the skin by the bacterium S. aureus is extremely prevalent in those with atopic dermatitis.[46] Abnormalities in the skin barrier of persons with AD are exploited by S. aureus to trigger cytokine expression, thus aggravating the condition.[47] However, atopic dermatitis is
non-communicable and therefore could not be directly caused by a highly
infectious organism. Furthermore, there is insufficient evidence for the effectiveness of anti-staphylococcal treatments for treating S. aureus in infected or uninfected eczema.[48]
Hard water
The prevalence of atopic dermatitis in children may be linked to the level of
calcium carbonate or "
hardness" of household drinking water.[49][50] Living in areas with hard water may also play a part in the development of AD in early life. However, when AD is already established, using
water softeners at home does not reduce the severity of the symptoms.[50]
Disruption of the epidermal barrier is thought to play an integral role in the
pathogenesis of AD.[33] Disruptions of the epidermal barrier allows allergens to penetrate the epidermis to deeper layers of the skin. This leads to activation of
epidermal inflammatory dendritic and
innate lymphoid cells which subsequently attracts
Th2 CD4+ helper T cells to the skin.[33] This dysregulated Th2 inflammatory response is thought to lead to the eczematous lesions.[33] The Th2 helper T cells become activated, leading to the release of inflammatory cytokines including
IL-4,
IL-13 and
IL-31 which activate downstream
Janus kinase (Jak) pathways. The active Jak pathways lead to inflammation and downstream activation of
plasma cells and
B lymphocytes which release antigen specific
IgE contributing to further inflammation.[33] Other CD4+ helper T-cell pathways thought to be involved in atopic dermatitis inflammation include the Th1,
Th17, and Th22 pathways.[33] Some specific CD4+ helper T-cell inflammatory pathways are more commonly activated in specific ethnic groups with AD (for example, the Th-2 and Th-17 pathways are commonly activated in Asian people) possibly explaining the differences in phenotypic presentation of atopic dermatitis in specific populations.[33]
Mutations in the filaggrin gene, FLG, also cause impairment in the skin barrier that contributes to the pathogenesis of AD.[33] Filaggrin is produced by epidermal skin cells (
keratinocytes) in the
horny layer of the epidermis. Filaggrin stimulates skin cells to release moisturizing factors and lipid matrix material, which cause adhesion of adjacent keratinocytes and contributes to the skin barrier.[33] A loss-of-function mutation of filaggrin causes loss of this lipid matrix and external moisturizing factors, subsequently leading to disruption of the skin barrier. The disrupted skin barrier leads to transdermal water loss (leading to the
xerosis or dry skin commonly seen in AD) and antigen and allergen penetration of the epidermal layer.[33] Filaggrin mutations are also associated with a decrease in natural antimicrobial peptides found on the skin; subsequently leading to disruption of skin flora and bacterial overgrowth (commonly Staphylococcus aureus overgrowth or colonization).[33]
Atopic dermatitis is also associated with the release of pruritogens (molecules that stimulate
pruritus or itching) in the skin.[33] Keratinocytes,
mast cells,
eosinophils and
T-cells release pruritogens in the skin; leading to activation of
Aδ fibers and
Group C nerve fibers in the
epidermis and
dermis contributing to sensations of pruritus and pain.[33] The pruritogens include the Th2 cytokines IL-4, IL-13, IL-31, histamine, and various neuropeptides.[33] Mechanical stimulation from scratching lesions can also lead to the release of pruritogens contributing to the itch-scratch cycle whereby there is increased pruritus or itch after scratching a lesion.[33] Chronic scratching of lesions can cause thickening or
lichenification of the skin or
prurigo nodularis (generalized nodules that are severely itchy).[33]
Diagnosis
AD is typically
diagnosed clinically, meaning it is based on signs and symptoms alone, without special testing.[53] Several different criteria developed for research have also been validated to aid in diagnosis.[54] Of these, the UK Diagnostic Criteria, based on the work of Hanifin and
Rajka, has been the most widely validated.[54][55]
People must have
itchy skin, or evidence of rubbing or scratching, plus three or more of:
Skin creases are involved - flexural dermatitis of fronts of
ankles,
antecubital fossae,
popliteal fossae, skin around eyes, or neck, (or cheeks for children under 10)
History of
asthma or
allergic rhinitis (or family history of these conditions if patient is a child ≤4 years old)
Symptoms began before age 2 (can only be applied to patients ≥4 years old)
No cure for AD is known, although treatments may reduce the severity and frequency of flares.[18] The most commonly used topical treatments for AD are topical corticosteroids (to get control of flare-ups) and moisturisers (emollients) to help keep control.[56] Clinical trials often measure the efficacy of treatments with a severity scale such as the
SCORAD index or the
Eczema Area and Severity Index.[53][57]
Moisturisers
Daily basic care is intended to stabilize the barrier function of the skin to mitigate its sensitivity to irritation and penetration of allergens. Affected persons often report that improvement of skin hydration parallels with improvement in AD symptoms.
Moisturisers (or emollients) can improve skin comfort and may reduce disease flares.[58] They can be used as leave-on treatments, bath additives or
soap substitutes. There are many different products but the majority of leave-on treatments (least to most greasy) are
lotions,
creams,
gels or
ointments. All of the different types of moisturisers are equally effective so people need to choose one or more products based on what suits them, according to their age, body site effected, climate/season and personal preference.[59] Non-medicated prescription moisturisers may also be no more effective than
over-the-counter moisturisers.[60]
There is no evidence that the additional use of emollient bath additives is beneficial.[61]
Medication
Topical
Corticosteroids applied directly on skin (
topical) have proven effective in managing atopic dermatitis.[18][19][60][62] Newer (second generation) corticosteroids, such as
fluticasone propionate and
mometasone furoate, are more effective and safer than older ones. Strong and moderate corticosteroids work better than weaker ones. They are also generally safe when used in intermittent bursts to treat AD flare-ups. Applying once daily is as effective as twice or more daily application.[60][62]
Certain
monoclonal antibodies (mAb) are highly effective for managing atopic dermatitis, but modestly increase the risk of
conjunctivitis.[63][73] Among monoclonal antibodies,
dupilumab (Dupixent) and
tralokinumab (Adtralza, Adbry) are approved to treat moderate-to-severe eczema in the US and the EU.[74][75][76][77]Lebrikizumab (Ebglyss) is also approved in the EU for treating moderate-to-severe AC[78] but in the US its approval was declined due to manufacturing issues.[79]
Some
JAK inhibitors such as
abrocitinib, trade name Cibinqo,[80] and
upadacitinib, trade name Rinvoq,[81] have been approved in the US for the treatment of moderate-to-severe eczema as of January 2022. These treatments are among the most effective systemic treatments, but have uncertain serious harms.[63][73]
Allergen immunotherapy may be effective in relieving symptoms of AD but it also comes with an increased risk of
adverse events.[82] This treatment consists of a series of injections or drops under the tongue of a solution containing the allergen.[83]
Antibiotics, either by mouth or applied topically, are commonly used to target overgrowth of S. aureus in the skin of people with AD, but there is insufficient evidence for the effectiveness of anti-staphylococcal treatments for treating S. aureus in infected or uninfected eczema.[48]
Diet
The role of
vitamin D on atopic dermatitis is not clear, but vitamin D supplementation may improve its symptoms.[84][85][86]
Several
probiotics seem to have a positive effect, with a roughly 20% reduction in the rate of AD.[89][90][91] Probiotics containing multiple
strains of bacteria seem to work the best.[92]
In people with celiac disease or
nonceliac gluten sensitivity, a gluten-free diet improves their symptoms and prevents the occurrence of new outbreaks.[42][43]
Use of blood specific
IgE or
skin prick tests to guide dietary exclusions with the aim of improving disease severity or control is controversial. Clinicians vary in their use of these tests for this purpose and there are very limited evidence of any benefit.[93]
Lifestyle
Health professionals often recommend that people with AD bathe regularly in lukewarm baths, especially in salt water, to moisten their skin.[19][94] Dilute
bleach baths may be helpful for people with moderate and severe eczema, but only for patients with Staphylococcus aureus.[95]
Avoiding
woolen clothing or scratchy fibres is usually recommended for people with AD as they can trigger a flare.[96][97]
Self-management
Treatment regimens can be confusing and written action plans may support people to know what treatments to use where and when.[98]
A website supporting self-management has been shown to improve AD symptoms for parents, children, adolescents and young adults.[99][100]
Light
Phototherapic treatment involves exposure to broad- or narrow-band
ultraviolet (UV) light. UV radiation exposure has been found to have a localized immunomodulatory effect on affected tissues and may be used to decrease the severity and frequency of flares.[101][102] Among the different types of phototherapies only narrowband (NB) ultraviolet B (UVB) exposure might help with the severity of AD and ease itching.[73][103] However, UV radiation has also been implicated in various types of skin cancer, and thus UV treatment is not without risk.[104]UV phototherapy is not indicated in young adults and children due to this risk of skin cancer with prolonged use or exposure.[33]
Alternative medicine
While several
Chinese herbal medicines are intended for treating atopic eczema, no conclusive evidence shows that these treatments, taken by mouth or applied topically, reduce the severity of eczema in children or adults.[105]
Burden of disease
Atopic dermatitis significantly impairs the
quality of life of affected individuals. [106][107] The impact of AD extends beyond physical symptoms, encompassing substantial humanistic and psychosocial effects. Its burden is significant, especially given the high indirect costs and psychological impacts on quality of life.[106][108]
According to the
Global Burden of Disease Study, AD is the skin disease with the highest
disability-adjusted life year burden and ranks in the top 15 of all nonfatal diseases. In comparison with other dermatological conditions like psoriasis and urticaria, AD presents a significantly higher burden.[107]
While AD remains incurable, reducing its severity can significantly alleviate its burden. Understanding the extent of the burden of AD can aid in better resource allocation and prioritization of interventions, benefiting both patients and healthcare systems.[109]
Humanistic burden
AD significantly decreases the quality of life by affecting various aspects of people's lives. The psychological impact, often resulting in conditions like depression and anxiety, is a major factor leading to decreased quality of life. Sleep disturbances, commonly reported in people with AD, further contribute to the humanistic burden, affecting daily productivity and concentration.[106][110]
Clinical and economic burden
Economically, AD imposes a substantial burden on healthcare systems, with the average direct cost per patient estimated at 4411 USD and the average indirect cost reaching 9068 USD annually.[106] These figures highlight the considerable financial impact of the disease on healthcare systems and people with the condition.[111][112]
Productivity loss
AD also has a marked impact on productivity. The total number of days lost annually due to these factors is about 68.8 days for the general AD population, with
presenteeism accounting for the majority of these days.[106] The impact on productivity varies significantly with the severity of AD, with more severe cases resulting in higher numbers of days lost.[106][113]
Burden of disease in the Middle East and Africa
Atopic dermatitis leads to the highest loss in disability-adjusted life years compared to other skin diseases in the Middle East and Africa.[114] Patients with AD in these regions lose approximately 0.19
quality-adjusted life years (QALYs) annually due to the disease. Egypt experiences the highest QALY loss and Kuwait the lowest.[114]
The average annual healthcare cost per patient varies is highest in the United Arab Emirates, estimated at US $3569, and lowest in Algeria at US $312. These costs are influenced by the economic status of each country and the cost of healthcare. Advanced treatments like targeted therapies and phototherapy are among the main cost drivers.[114]
Indirect costs, primarily due to productivity loss from
absenteeism and presenteeism average about 67% in these countries. Indirect costs in Saudi Arabia are the highest in the area, estimated at US $364 million.[114] Factors like mental health impact, side effects of treatments, and other indirect costs such as personal care products are not fully accounted for in these estimates, suggesting that the actual burden might be even higher.[114]
Epidemiology
Since the beginning of the 20th century, many inflammatory skin disorders have become more common; AD is a classic example of such a disease. Although AD was previously considered primarily a childhood disease, it is now recognized as highly prevalent in adults, with an estimated adult prevalence of 3-5% globally.[106][107] It now affects 15–30% of children and 2–10% of adults in developed countries, and in the United States has nearly tripled in the past 30–40 years.[19][115] Over 15 million American adults and children have AD.[116]
Society and culture
Conspiracy theories
A number of false and conspiratorial claims about AD have emerged on the internet and have been amplified by social media. These
conspiracy theories include, among others, claims that AD is caused by
5G,
formaldehyde in food,
vaccines, and topical steroids. Various unproven theories also claim that
vegan diets,
apple cider vinegar,
calendula, and
witch hazel can cure AD and that
air purifiers reduce the risk of developing AD.[117]
^Ong PY, Boguniewicz J, Chu DK (January 2023). "Skin Antiseptics for Atopic Dermatitis: Dissecting Facts From Fiction". The Journal of Allergy and Clinical Immunology. In Practice. 11 (5): 1385–1390.
doi:
10.1016/j.jaip.2023.01.012.
PMID36702247.
S2CID256222372.
^Oykhman P, Dookie J, Al-Rammahy H, de Benedetto A, Asiniwasis RN, LeBovidge J, et al. (October 2022). "Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis". The Journal of Allergy and Clinical Immunology. In Practice. 10 (10): 2657–2666.e8.
doi:
10.1016/j.jaip.2022.06.044.
PMID35987995.
S2CID250710625.
^Friedmann PS, Holden CA (January 2004). "Atopic Dermatitis". In Burns T, Breathnach S, Cox N, Griffiths C (eds.). Rook's Textbook of Dermatology. Malden, Massachusetts, USA: Blackwell Publishing, Inc. pp. 755–786.
doi:
10.1002/9780470750520.ch18.
ISBN978-0-470-75052-0.
^
abKwatra SG, Tey HL, Ali SM, Dabade T, Chan YH, Yosipovitch G (June 2012). "The infra-auricular fissure: a bedside marker of disease severity in patients with atopic dermatitis". Journal of the American Academy of Dermatology. 66 (6): 1009–1010.
doi:
10.1016/j.jaad.2011.10.031.
PMID22583715.
^
abcdeKim BS (21 January 2014). Fritsch P, Vinson RP, Perry V, Quirk CM, James WD (eds.).
"Atopic Dermatitis". Medscape Reference. WebMD.
Archived from the original on 10 February 2014. Retrieved 3 March 2014.
^Brehler R (2009). "Atopic Dermatitis". In Lang F (ed.). Encyclopedia of molecular mechanisms of diseases. Berlin: Springer.
ISBN978-3-540-67136-7.
^Chaudhary PP, Myles IA, Zeldin J, Dabdoub S, Deopujari V, Baveja R, et al. (October 2023). "Shotgun metagenomic sequencing on skin microbiome indicates dysbiosis exists prior to the onset of atopic dermatitis". Allergy. 78 (10): 2724–2731.
doi:
10.1111/all.15806.
ISSN1398-9995.
PMC 10543534.
PMID37422700.
^
abBerdyshev E, Kim J, Kim BE, Goleva E, Lyubchenko T, Bronova I, et al. (May 2023). "Stratum corneum lipid and cytokine biomarkers at age 2 months predict the future onset of atopic dermatitis". The Journal of Allergy and Clinical Immunology. 151 (5): 1307–1316.
doi:
10.1016/j.jaci.2023.02.013.
ISSN1097-6825.
PMID36828081.
S2CID255078763.
^Irvine AD, McLean WH, Leung DY (October 2011). "Filaggrin mutations associated with skin and allergic diseases". The New England Journal of Medicine (Review). 365 (14): 1315–1327.
doi:
10.1056/NEJMra1011040.
PMID21991953.
^Pelucchi C, Galeone C, Bach JF, La Vecchia C, Chatenoud L (September 2013). "Pet exposure and risk of atopic dermatitis at the pediatric age: a meta-analysis of birth cohort studies". The Journal of Allergy and Clinical Immunology. 132 (3): 616–622.e7.
doi:
10.1016/j.jaci.2013.04.009.
hdl:2434/239729.
PMID23711545.
^
abFasano A, Sapone A, Zevallos V, Schuppan D (May 2015).
"Nonceliac gluten sensitivity". Gastroenterology (Review). 148 (6): 1195–1204.
doi:10.1053/j.gastro.2014.12.049.
PMID25583468. Many patients with celiac disease also have atopic disorders. About 30% of patients' allergies with gastrointestinal (GI) symptoms and mucosal lesions, but negative results from serologic (TG2 antibodies) or genetic tests (DQ2 or DQ8 genotype) for celiac disease, had reduced GI and atopic symptoms when they were placed on GFDs. These findings indicated that their symptoms were related to gluten ingestion.
^Goh CL, Wong JS, Giam YC (September 1997). "Skin colonization of Staphylococcus aureus in atopic dermatitis patients seen at the National Skin Centre, Singapore". International Journal of Dermatology. 36 (9): 653–657.
doi:
10.1046/j.1365-4362.1997.00290.x.
PMID9352404.
S2CID3112669.
^
abJabbar-Lopez ZK, Ung CY, Alexander H, Gurung N, Chalmers J, Danby S, et al. (March 2021). "The effect of water hardness on atopic eczema, skin barrier function: A systematic review, meta-analysis". Clinical and Experimental Allergy. 51 (3): 430–451.
doi:
10.1111/cea.13797.
PMID33259122.
S2CID227245344.
^Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD (January 2016). "Targeting key proximal drivers of type 2 inflammation in disease". Nature Reviews. Drug Discovery. 15 (1): 35–50.
doi:
10.1038/nrd4624.
PMID26471366.
S2CID2421591.
^
abWilliams HC, Burney PG, Pembroke AC, Hay RJ (September 1994). "The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation". The British Journal of Dermatology. 131 (3): 406–416.
doi:
10.1111/j.1365-2133.1994.tb08532.x.
PMID7918017.
S2CID37406163.
^Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, et al. (January 2023). "Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis". The Lancet. Child & Adolescent Health. 7 (1): 13–25.
doi:
10.1016/S2352-4642(22)00283-8.
PMID36370744.
S2CID253470127.
^Chin WK, Lee SW (October 2018). "A systematic review on the off-label use of montelukast in atopic dermatitis treatment". International Journal of Clinical Pharmacy. 40 (5): 963–976.
doi:
10.1007/s11096-018-0655-3.
PMID29777328.
S2CID21753181.
^Jaros J, Wilson C, Shi VY (August 2020). "Fabric Selection in Atopic Dermatitis: An Evidence-Based Review". American Journal of Clinical Dermatology. 21 (4): 467–482.
doi:
10.1007/s40257-020-00516-0.
PMID32440827.
S2CID218761019.
^Beattie PE, Finlan LE, Kernohan NM, Thomson G, Hupp TR, Ibbotson SH (May 2005). "The effect of ultraviolet (UV) A1, UVB and solar-simulated radiation on p53 activation and p21". The British Journal of Dermatology. 152 (5): 1001–1008.
doi:
10.1111/j.1365-2133.2005.06557.x.
PMID15888160.
S2CID22191753.
^Saito H (August 2005). "Much atopy about the skin: genome-wide molecular analysis of atopic eczema". International Archives of Allergy and Immunology. 137 (4): 319–325.
doi:
10.1159/000086464.
PMID15970641.
S2CID20040720.
^O'Connor C, Murphy M (December 2021). "Scratching the surface: a review of online misinformation and conspiracy theories in atopic dermatitis". Clinical and Experimental Dermatology. 46 (8): 1545–1547.
doi:
10.1111/ced.14679.
hdl:10468/11402.
PMID33864398.
S2CID233278383.
^Totté JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG (October 2016). "Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis". The British Journal of Dermatology. 175 (4): 687–695.
doi:
10.1111/bjd.14566.
PMID26994362.
S2CID23617550.